U.S. Therapeutic Plasma Exchange Market Overview
The U.S Therapeutic Plasma Exchange Market size is estimated to reach $280 million by 2027. Furthermore, it is poised to grow at a CAGR of 6.2% over the forecast period of 2022-2027. Therapeutic Plasma exchange or TYP is the most preferred form of therapy for patients suffering from neurological diseases which includes multiple sclerosis and other forms. The procedure starts by collecting blood from the patient’s body and is then replaced with another fluid such as albumin solution or donor’s plasma. The plasma contains antibodies, and which allow the body to fight a particular antigen or disease. In the cases of Guillain-Barré syndrome, TPE has been recommended as the most favorable treatment. In the following condition, the patient’s body (immune system) starts to damage the nerves. Myasthenia gravis treatment, which is also a form of immune disorder can be rectified with the help of TPE. In the following conditions, the body’s cell and nerves communication breaks down and causes problems such as double vision, difficulty with chewing and swallowing. Patients afflicted after the multiple sclerosis diagnosis were also adopted for therapeutic plasma exchange. Owing to an increase in the prevalence of auto-immune diseases coupled with technological advancements to ease the process and the growing geriatric population are some of the factors driving the U.S therapeutic plasma exchange industry forward in the projected period of 2022-2027.
The report: “U.S. Therapeutic Plasma Exchange Market Forecast (2022-2027)”, by Industry ARC covers an in-depth analysis of the following segments of the U.S. Therapeutic Plasma Exchange Market.
By Indication- Neurological Disorders, Hematology
Disorders, Renal Disorders, Metabolic Disorders, and Others.
By End User- Blood Collection Centers, Hospitals and Clinics, Transfusion Centers, and Others.
By Product- Consumables, and Devices.
By Technology- Centrifugation, and Membrane Separation.
- The therapeutic plasma exchange market in the U.S. is propelled owing to multiple factors. For example, owing to the pandemic, PTE was considered an effective therapy treatment. Moreover, it has been in use for a long time before, but its knowledge to the masses was only possible in the pandemic year. Additionally, the manufacturers of centrifugal machines are continually upgrading the machines, which allows the user to experience no pain.
- Owing an increase in chronic illnesses and a higher prevalence of neurological disorders have been identified as key drivers. However, since the cost of setting an apheresis device is high, afflicted patients are identifying alternative routes such as leasing or renting the machine for their use. The following is a grave market challenge.
- A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the U.S therapeutic plasma exchange market report.
U.S. Therapeutic Plasma Exchange Market- Indication (%) for 2021.
For more details on this report - Request for Sample
U.S. Therapeutic Plasma Exchange Market Segmentation Analysis- By Technology
The U.S therapeutic plasma exchange market based on the technology can be further segmented into Centrifugation and Membrane Separation. The Centrifugation separation or cTPE segment held a dominant market share in the year 2021. It is owing to its multi-functional use in various applications. Moreover, as per various case studies analyzed, a lot of benefits were observed while the out-patient care centers change their machines from membrane separation to centrifugal separation. For example, the patient felt less nauseous, as per the trial, the patient felt nauseated and cold post mTPE procedure, and additionally the patient developed radiocephalic AVF post mTPE procedures. However, post cTPE methodology patient didn’t feel such symptoms. Additionally, there was no circuit clogging or clotting observed.
Moreover, the centrifugation or cTPE segment is estimated to be the fastest-growing, with a CAGR of 6.8% over the forecast period of 2022-2027. It is owing to the various benefits it offers over the others. The plasma removal efficiency is superior, total exchange time is low, clotting events are negligible, and patient satisfaction is pen-ultimate. Additionally, marketers are readily rolling out the following technology-based products in the market, this would allow for segment growth.
U.S. Therapeutic Plasma Exchange Market Segmentation Analysis- By Indication
The U.S therapeutic plasma exchange market based on the indication can be further segmented into Neurological Disorders, Hematology Disorders, Renal Disorders, Metabolic Disorders, and Others. Neurological disorders held a dominant market share in the year 2021. It is owing to the rising number of cases now being readily diagnosed due to increasing medical literacy. Moreover, as per the CDC, 20,000-40,000 cases related to Guillain-Barré syndrome were found. Furthermore, multiple sclerosis’s prevalences have been close to 2 million cases a year. The following have readily augmented the growth of the therapeutic plasma exchange market.
Renal disorders are estimated to be the fastest-growing segment, with a CAGR of 7.0% over the forecast period of 2022-2027. It is owing to the high prevalence of the disease in the US. According to CDC, 1 in 7 or up to 15% of the US adults have chronic kidney disease, which would ultimately lead them to have a TPE or organ transplant. As per various statistics, every ten minutes a name gets added to the organ transplant list, of which the majority is for kidneys. The advent of new products pertaining to help the following diseases will allow the growth of this segment.
U.S. Therapeutic Plasma Exchange Market Driver
The rising incidence of neurological disorders across the region will supplant the growth of the plasma exchange market.
The prevalence of auto-immune disorders has been increasing at a steady pace in the region. It is owing to multiple factors such as sedentary lifestyle, genetic coding, and lately the age. As per the rare disease organization, the auto-immune disease affects approximately 14-40 per 100,000 individuals in the US. Moreover, the country has deciphered the increase in incidence owing to better patient symptom identification. Additionally, women are more prone to have myasthenia gravis than men. Additionally, the most common factor noticed in all the cases is that the majority falls under the aging population. As per US CDC estimates, the senior population will break even the younger adults by 2034. Additionally, the senior population will hold a major part of the entire population by 2040. The following factors will largely benefit the U.S therapeutic plasma exchange market.
The efficacy of therapeutic plasma exchange over the other forms of treatment has readily helped the market growth.
TPE has been regarded and holds evidence for its strong performance in the improvement of neurological disorders and has also set place as an alternative to IVIGs. Cross-relational studies have been actively conducted across the practice to check for results and offer TPE as the alternative, and it has not yet disappointed. In a study conducted, 37 patients were treated with TPE, who have had MS relapses and their treatment of corticosteroid was unresponsive. Moreover, the researchers' trial also wanted to check that post TPE session will the body become more responsive to corticosteroid, and to their surprise, the results followed. Out of 37, ten people showed improvement, twenty-four showed moderate improvement, while three showed no-response. Hence, TPE treatment promises great results.
U.S. Therapeutic Plasma Exchange Market Challenges
The cost pertaining to apheresis devices is hampering the growth of the market.
As per our review, the average cost of apheresis typically can go up to $50,000. Additionally, the disposables can cost anywhere between $1500 to $3000. The following cost does not motivate the new physicians or small set-ups to purchase a new machine. Hence, the end-users are now looking to lease machines on a monthly or annual basis to bring down the relative costs. For example, an annual subscription can drastically reduce the impact on physicians. For example, if the machine is taken on lease for five years, with an annual subscription fee of $8,000, the cost gets evenly spread across the month, thereby reducing the financial impact on end-users and new-age start-ups.
U.S. Therapeutic Plasma Exchange Market Competitive Landscape
Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the U.S Therapeutic Plasma Exchange Market. The top 10 U.S Therapeutic Plasma Exchange Market companies are-
- Terumo BCT, Inc.
- Fresenius SE & Co. KGaA
- Haemonetics Corporation
- Asahi Kasei Medical Co. Ltd
- B. Braun Melsungen AG
- Baxter International Inc.
- Cerus Corporation
- Kaneka Corporation
- Kawasumi Laboratories, Inc.
- Nikkiso Co., Ltd.
- In October 2021, Eliaz Therapeutics announced its therapeutic apheresis devices known as XGAL-3. The device is capable of removing galectin-3 from one's blood. The mentioned enzyme is the leading modulator for organ inflammation and fibrosis. Additionally, the company focuses on using the device to treat Acute Kidney Injury, which it forecasts would be a leading mortality disease in the future.
- In January 2021, Cerus Corporation received a nod for its
product known as INTERCEPT, which allows cryoprecipitate, which in turn makes
it favorable for therapeutic plasma exchange. The device’s generic name has
been kept under “Pathogen Reduction System for Plasma”, and patients suffering
from thrombocytopenic purpura (TTP) can potentially use the treatment.
Therapy Market- Forecast (2022-2027)
Report Code- HCR 0458